Puma Exec's Brother Traded On Cancer Drug Info, SEC Says

Law360, New York (December 7, 2017, 4:32 PM EST) -- The U.S. Securities and Exchange Commission on Wednesday filed a suit in Florida federal court accusing the brother of a Puma Biotechnology Inc. executive of reaping $107,000 in illegal profits through insider trading based on conversations between the two related to the development of a cancer drug.

In the complaint, the SEC said Stephen J. Leonard on four occasions bought Puma stock after speaking to his sibling in the weeks ahead of a July 22, 2014, announcement by the company that its cancer drug neratinib was...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Securities and Exchange Commission v. Leonard


Case Number

8:17-cv-02926

Court

Florida Middle

Nature of Suit

Securities/Commodities

Judge

James S. Moody, Jr

Date Filed

December 6, 2017

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.